{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T20:25:29Z","timestamp":1787257529753,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jbc.2026.113260","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:56:19Z","timestamp":1781826979000},"page":"113260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Overcoming cetuximab resistance in HNSCC by Hsp90 inhibition to enhance EGFR degradation"],"prefix":"10.1016","volume":"302","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2735-1682","authenticated-orcid":false,"given":"Ranjit K.","family":"Mehta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjia","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7785-3536","authenticated-orcid":false,"given":"Krithika","family":"Suresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore S.","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4359-6962","authenticated-orcid":false,"given":"Mukesh K.","family":"Nyati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbc.2026.113260_bib1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1535-6108(04)00112-6","article-title":"Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression","volume":"5","author":"Chung","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbc.2026.113260_bib2","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1200\/JCO.2005.04.8306","article-title":"Epidermal growth factor receptor biology in head and neck cancer","volume":"24","author":"Kalyankrishna","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbc.2026.113260_bib3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc2982","article-title":"The molecular biology of head and neck cancer","volume":"11","author":"Leemans","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jbc.2026.113260_bib4","first-page":"7350","article-title":"Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma","volume":"62","author":"Ang","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbc.2026.113260_bib5","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1200\/JCO.2006.07.2587","article-title":"Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas","volume":"24","author":"Chung","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbc.2026.113260_bib6","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1200\/JCO.2006.06.6605","article-title":"Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer","volume":"25","author":"Temam","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbc.2026.113260_bib7","doi-asserted-by":"crossref","first-page":"100863","DOI":"10.1016\/j.drup.2022.100863","article-title":"Genetic alterations shaping tumor response to anti-EGFR therapies","volume":"64","author":"Vaquero","year":"2022","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.jbc.2026.113260_bib8","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1073\/pnas.80.5.1337","article-title":"Growth-stimulation of A431 cells by epidermal growth-factor - identification of high-affinity receptors for epidermal growth-factor by an anti-receptor monoclonal-antibody","volume":"80","author":"Kawamoto","year":"1983","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2026.113260_bib9","doi-asserted-by":"crossref","first-page":"591139","DOI":"10.3389\/fimmu.2020.591139","article-title":"Tumor-specific antibody, cetuximab, enhances the in situ vaccine effect of radiation in immunologically cold head and neck squamous cell carcinoma","volume":"11","author":"Jin","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jbc.2026.113260_bib10","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2006.06.7447","volume":"25","author":"Vermorken","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbc.2026.113260_bib11","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/annonc\/mdq588","article-title":"Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and\/or metastatic squamous cell carcinoma of the head and neck: EXTREME study","volume":"22","author":"Licitra","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbc.2026.113260_bib12","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.canlet.2020.10.035","article-title":"EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation","volume":"498","author":"Alsahafi","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jbc.2026.113260_bib13","doi-asserted-by":"crossref","first-page":"208","DOI":"10.20892\/j.issn.2095-3941.2019.0153","article-title":"Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma","volume":"17","author":"Leblanc","year":"2020","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.jbc.2026.113260_bib14","first-page":"57","article-title":"KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med."},{"key":"10.1016\/j.jbc.2026.113260_bib15","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1470-2045(08)70206-7","article-title":"Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents:: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer","volume":"9","author":"Linardou","year":"2008","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jbc.2026.113260_bib16","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nature11156","article-title":"Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer","volume":"486","author":"Misale","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jbc.2026.113260_bib17","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.1158\/1078-0432.CCR-11-0861","article-title":"Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer","volume":"17","author":"Argiris","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbc.2026.113260_bib18","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1593\/neo.12986","article-title":"Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors","volume":"14","author":"Ahsan","year":"2012","journal-title":"Neoplasia"},{"key":"10.1016\/j.jbc.2026.113260_bib19","doi-asserted-by":"crossref","first-page":"26879","DOI":"10.1074\/jbc.M113.492280","article-title":"Destabilization of the Epidermal Growth Factor Receptor (EGFR) by a peptide that inhibits EGFR binding to heat shock protein 90 and receptor dimerization","volume":"288","author":"Ahsan","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbc.2026.113260_bib20","doi-asserted-by":"crossref","first-page":"777","DOI":"10.4161\/cbt.11.9.15050","article-title":"Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab","volume":"11","author":"Brand","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.jbc.2026.113260_bib21","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","article-title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"Karapetis","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbc.2026.113260_bib22","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3389\/fonc.2019.00800","article-title":"Rethink of EGFR in cancer with its kinase independent function on board","volume":"9","author":"Thomas","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jbc.2026.113260_bib23","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ccr.2008.03.015","article-title":"Survival of cancer cells is maintained by EGFR independent of its kinase activity","volume":"13","author":"Weihua","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbc.2026.113260_bib24","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/jnci\/djm135","article-title":"Drug resistance and the solid tumor microenvironment","volume":"99","author":"Tredan","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jbc.2026.113260_bib25","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1200\/JCO.2014.59.4812","article-title":"Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer","volume":"33","author":"Van Cutsem","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbc.2026.113260_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.150711","article-title":"Investigating NanoLuc-EGFR engineered cell lines for real-time monitoring of EGFR protein dynamics in live cells","volume":"733","author":"Mehta","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jbc.2026.113260_bib27","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1038\/nprot.2006.339","article-title":"Clonogenic assay of cells in vitro","volume":"1","author":"Franken","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.jbc.2026.113260_bib28","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1158\/0008-5472.CAN-05-2665","article-title":"Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma","volume":"66","author":"Chun","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbc.2026.113260_bib29","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1158\/1078-0432.CCR-19-3102","article-title":"Low-dose Hsp90 inhibitor selectively radiosensitizes HNSCC and pancreatic xenografts","volume":"26","author":"Mehta","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbc.2026.113260_bib30","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1006\/jmcc.1998.0655","article-title":"The statistics of synergism","volume":"30","author":"Slinker","year":"1998","journal-title":"J. Mol. Cell Cardiol."}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925826021320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925826021320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T19:46:52Z","timestamp":1787255212000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925826021320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0021925826021320"],"URL":"https:\/\/doi.org\/10.1016\/j.jbc.2026.113260","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming cetuximab resistance in HNSCC by Hsp90 inhibition to enhance EGFR degradation","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbc.2026.113260","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"113260"}}